Results of live donor liver transplantation in patients with hepatitic C virus infection

The HCV 3 trial experience

Linda Sher, Linda Jennings, Steven Rudich, Sophoclis P. Alexopoulos, George Netto, Lewis Teperman, Milan Kinkhabwala, Robert S. Brown, Elizabeth Pomfret, Goran Klintmalm

Research output: Contribution to journalArticle

Abstract

Chronic hepatitis C virus (HCV) is the most common disease indication for liver transplantation (LT). Outcomes are compromised by near universal recurrence of HCV. A prospective multi-center randomized study to evaluate immunosuppressive strategies in HCV+ transplant recipients provided the opportunity to assess impact of live donor (LD) LT. Two hundred and ninety-five patients undergoing LT for HCV (260 deceased donor [DD] recipients/35 LD recipients), randomized to three regimens, were followed for twoyr for patient and graft survival and rate and severity of recurrent HCV. Biopsies were performed at baseline, 3, 12, and 24months. One- and two-yr patient survival for LD recipients was 88.1% and 81.1% vs. 90.5% and 84.6% for DD recipients (p=0.5665). One- and two-yr graft survival for LD recipients was 82.9% and 76.2% vs. 87.9% and 81.7% for DD recipients (p=0.3921). Recurrent HCV did not account for more deaths or graft losses in the LD recipients. In this prospective study, controlled for immunosuppression, use of LD organs did not increase the rate or severity of HCV recurrence. The more elective nature of LDLT affords an opportunity to manipulate donor and recipient factors that can impact upon outcomes.

Original languageEnglish (US)
Pages (from-to)502-509
Number of pages8
JournalClinical Transplantation
Volume26
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Virus Diseases
Hepacivirus
Liver Transplantation
Tissue Donors
Graft Survival
Recurrence
Chronic Hepatitis C
Immunosuppressive Agents
Immunosuppression
Survival Rate
Prospective Studies
Transplants
Biopsy
Survival

Keywords

  • Hepatitis C
  • Live donor liver transplant
  • Liver transplantation
  • Outcomes
  • Recurrence

ASJC Scopus subject areas

  • Transplantation

Cite this

Sher, L., Jennings, L., Rudich, S., Alexopoulos, S. P., Netto, G., Teperman, L., ... Klintmalm, G. (2012). Results of live donor liver transplantation in patients with hepatitic C virus infection: The HCV 3 trial experience. Clinical Transplantation, 26(3), 502-509. https://doi.org/10.1111/j.1399-0012.2011.01561.x

Results of live donor liver transplantation in patients with hepatitic C virus infection : The HCV 3 trial experience. / Sher, Linda; Jennings, Linda; Rudich, Steven; Alexopoulos, Sophoclis P.; Netto, George; Teperman, Lewis; Kinkhabwala, Milan; Brown, Robert S.; Pomfret, Elizabeth; Klintmalm, Goran.

In: Clinical Transplantation, Vol. 26, No. 3, 05.2012, p. 502-509.

Research output: Contribution to journalArticle

Sher, L, Jennings, L, Rudich, S, Alexopoulos, SP, Netto, G, Teperman, L, Kinkhabwala, M, Brown, RS, Pomfret, E & Klintmalm, G 2012, 'Results of live donor liver transplantation in patients with hepatitic C virus infection: The HCV 3 trial experience', Clinical Transplantation, vol. 26, no. 3, pp. 502-509. https://doi.org/10.1111/j.1399-0012.2011.01561.x
Sher, Linda ; Jennings, Linda ; Rudich, Steven ; Alexopoulos, Sophoclis P. ; Netto, George ; Teperman, Lewis ; Kinkhabwala, Milan ; Brown, Robert S. ; Pomfret, Elizabeth ; Klintmalm, Goran. / Results of live donor liver transplantation in patients with hepatitic C virus infection : The HCV 3 trial experience. In: Clinical Transplantation. 2012 ; Vol. 26, No. 3. pp. 502-509.
@article{3df7e7654e8e4743ac00611305a450bd,
title = "Results of live donor liver transplantation in patients with hepatitic C virus infection: The HCV 3 trial experience",
abstract = "Chronic hepatitis C virus (HCV) is the most common disease indication for liver transplantation (LT). Outcomes are compromised by near universal recurrence of HCV. A prospective multi-center randomized study to evaluate immunosuppressive strategies in HCV+ transplant recipients provided the opportunity to assess impact of live donor (LD) LT. Two hundred and ninety-five patients undergoing LT for HCV (260 deceased donor [DD] recipients/35 LD recipients), randomized to three regimens, were followed for twoyr for patient and graft survival and rate and severity of recurrent HCV. Biopsies were performed at baseline, 3, 12, and 24months. One- and two-yr patient survival for LD recipients was 88.1{\%} and 81.1{\%} vs. 90.5{\%} and 84.6{\%} for DD recipients (p=0.5665). One- and two-yr graft survival for LD recipients was 82.9{\%} and 76.2{\%} vs. 87.9{\%} and 81.7{\%} for DD recipients (p=0.3921). Recurrent HCV did not account for more deaths or graft losses in the LD recipients. In this prospective study, controlled for immunosuppression, use of LD organs did not increase the rate or severity of HCV recurrence. The more elective nature of LDLT affords an opportunity to manipulate donor and recipient factors that can impact upon outcomes.",
keywords = "Hepatitis C, Live donor liver transplant, Liver transplantation, Outcomes, Recurrence",
author = "Linda Sher and Linda Jennings and Steven Rudich and Alexopoulos, {Sophoclis P.} and George Netto and Lewis Teperman and Milan Kinkhabwala and Brown, {Robert S.} and Elizabeth Pomfret and Goran Klintmalm",
year = "2012",
month = "5",
doi = "10.1111/j.1399-0012.2011.01561.x",
language = "English (US)",
volume = "26",
pages = "502--509",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Results of live donor liver transplantation in patients with hepatitic C virus infection

T2 - The HCV 3 trial experience

AU - Sher, Linda

AU - Jennings, Linda

AU - Rudich, Steven

AU - Alexopoulos, Sophoclis P.

AU - Netto, George

AU - Teperman, Lewis

AU - Kinkhabwala, Milan

AU - Brown, Robert S.

AU - Pomfret, Elizabeth

AU - Klintmalm, Goran

PY - 2012/5

Y1 - 2012/5

N2 - Chronic hepatitis C virus (HCV) is the most common disease indication for liver transplantation (LT). Outcomes are compromised by near universal recurrence of HCV. A prospective multi-center randomized study to evaluate immunosuppressive strategies in HCV+ transplant recipients provided the opportunity to assess impact of live donor (LD) LT. Two hundred and ninety-five patients undergoing LT for HCV (260 deceased donor [DD] recipients/35 LD recipients), randomized to three regimens, were followed for twoyr for patient and graft survival and rate and severity of recurrent HCV. Biopsies were performed at baseline, 3, 12, and 24months. One- and two-yr patient survival for LD recipients was 88.1% and 81.1% vs. 90.5% and 84.6% for DD recipients (p=0.5665). One- and two-yr graft survival for LD recipients was 82.9% and 76.2% vs. 87.9% and 81.7% for DD recipients (p=0.3921). Recurrent HCV did not account for more deaths or graft losses in the LD recipients. In this prospective study, controlled for immunosuppression, use of LD organs did not increase the rate or severity of HCV recurrence. The more elective nature of LDLT affords an opportunity to manipulate donor and recipient factors that can impact upon outcomes.

AB - Chronic hepatitis C virus (HCV) is the most common disease indication for liver transplantation (LT). Outcomes are compromised by near universal recurrence of HCV. A prospective multi-center randomized study to evaluate immunosuppressive strategies in HCV+ transplant recipients provided the opportunity to assess impact of live donor (LD) LT. Two hundred and ninety-five patients undergoing LT for HCV (260 deceased donor [DD] recipients/35 LD recipients), randomized to three regimens, were followed for twoyr for patient and graft survival and rate and severity of recurrent HCV. Biopsies were performed at baseline, 3, 12, and 24months. One- and two-yr patient survival for LD recipients was 88.1% and 81.1% vs. 90.5% and 84.6% for DD recipients (p=0.5665). One- and two-yr graft survival for LD recipients was 82.9% and 76.2% vs. 87.9% and 81.7% for DD recipients (p=0.3921). Recurrent HCV did not account for more deaths or graft losses in the LD recipients. In this prospective study, controlled for immunosuppression, use of LD organs did not increase the rate or severity of HCV recurrence. The more elective nature of LDLT affords an opportunity to manipulate donor and recipient factors that can impact upon outcomes.

KW - Hepatitis C

KW - Live donor liver transplant

KW - Liver transplantation

KW - Outcomes

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84862249740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862249740&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2011.01561.x

DO - 10.1111/j.1399-0012.2011.01561.x

M3 - Article

VL - 26

SP - 502

EP - 509

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 3

ER -